Valley Brook Capital Group Inc. Grows Position in Eli Lilly and Company (NYSE:LLY)

Valley Brook Capital Group Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,547 shares of the company’s stock after acquiring an additional 83 shares during the period. Valley Brook Capital Group Inc.’s holdings in Eli Lilly and Company were worth $1,371,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its holdings in Eli Lilly and Company by 19.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares in the last quarter. Quent Capital LLC grew its holdings in shares of Eli Lilly and Company by 5.3% in the first quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock valued at $3,846,000 after purchasing an additional 249 shares in the last quarter. W.H. Cornerstone Investments Inc. increased its position in Eli Lilly and Company by 44.6% in the first quarter. W.H. Cornerstone Investments Inc. now owns 1,213 shares of the company’s stock worth $944,000 after purchasing an additional 374 shares during the last quarter. Manchester Capital Management LLC raised its stake in Eli Lilly and Company by 33.9% during the first quarter. Manchester Capital Management LLC now owns 4,049 shares of the company’s stock valued at $3,150,000 after purchasing an additional 1,025 shares in the last quarter. Finally, Advisory Services Network LLC lifted its position in Eli Lilly and Company by 5.1% during the first quarter. Advisory Services Network LLC now owns 45,528 shares of the company’s stock valued at $35,418,000 after purchasing an additional 2,225 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $8.45 during trading hours on Thursday, reaching $784.83. 763,940 shares of the company were exchanged, compared to its average volume of 3,076,606. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The firm has a market cap of $745.05 billion, a PE ratio of 83.94, a price-to-earnings-growth ratio of 3.05 and a beta of 0.43. The stock’s 50-day moving average is $901.75 and its 200-day moving average is $867.32.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.66%. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Bank of America reduced their price objective on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Guggenheim raised their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Berenberg Bank boosted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, Sanford C. Bernstein started coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.